Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings
MZ Liao, D Lu, T Lu, L Gibiansky, R Deng… - Advanced Drug Delivery …, 2024 - Elsevier
The favorable benefit–risk profile of polatuzumab vedotin, as demonstrated in a pivotal
Phase Ib/II randomized study (GO29365; NCT02257567), coupled with the need for effective …
Phase Ib/II randomized study (GO29365; NCT02257567), coupled with the need for effective …
Integrated two‐analyte population pharmacokinetic model of polatuzumab vedotin in patients with non‐Hodgkin lymphoma
D Lu, T Lu, L Gibiansky, X Li, C Li… - CPT …, 2020 - Wiley Online Library
A two‐analyte integrated population pharmacokinetic (PK) model that simultaneously
describes concentrations of antibody‐conjugated monomethyl auristatin E (acMMAE) and …
describes concentrations of antibody‐conjugated monomethyl auristatin E (acMMAE) and …
Trastuzumab‐monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2‐positive human breast cancer
M Abdollahpour‐Alitappeh, M Lotfinia… - Journal of Cellular …, 2019 - Wiley Online Library
Targeted therapy using specific monoclonal antibodies (mAbs) conjugated to
chemotherapeutic agents or toxins has become one of the top priorities in cancer therapy …
chemotherapeutic agents or toxins has become one of the top priorities in cancer therapy …
[HTML][HTML] Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
Polatuzumab vedotin, marketed under the trade name POLIVY®, is a CD79b-targeted
antibody-drug conjugate that preferentially delivers a potent anti-mitotic agent (monomethyl …
antibody-drug conjugate that preferentially delivers a potent anti-mitotic agent (monomethyl …
[HTML][HTML] Application of a two-analyte integrated population pharmacokinetic model to evaluate the impact of intrinsic and extrinsic factors on the pharmacokinetics of …
D Lu, T Lu, R Shi, L Gibiansky, P Agarwal… - Pharmaceutical …, 2020 - Springer
Purpose The established two-analyte integrated population pharmacokinetic model was
applied to assess the impact of intrinsic/extrinsic factors on the pharmacokinetics (PK) of …
applied to assess the impact of intrinsic/extrinsic factors on the pharmacokinetics (PK) of …
[HTML][HTML] Breast cancer: risk factors, diagnosis and management
B Farhadihosseinabadi, F Hosseini, P Larki… - Medical Laboratory …, 2018 - goums.ac.ir
Breast cancer remains the most common cancer of women and one of the most common
causes of cancer-related deaths worldwide. In spite of major advances in breast cancer …
causes of cancer-related deaths worldwide. In spite of major advances in breast cancer …
Monomethyl auristatin E Exhibits Potent Cytotoxic Activity against Human Cancer Cell Lines SKBR3 and HEK293
M Abdollahpour-Alitappeh… - Novelty in …, 2017 - journals.sbmu.ac.ir
Background: Monomethyl auristatin E (MMAE) is a synthetic analog of dolastatin 10, a
compound originally isolated from the marine mollusk. MMAE, as a highly potent …
compound originally isolated from the marine mollusk. MMAE, as a highly potent …
Polatuzumab vedotin.
A Janíková - Remedia, 2020 - search.ebscohost.com
Summary Janikova A. Polatuzumab vedotin. Remedia 2020; 30: 532–535. Diffuse large B‑
cell lymphoma (DLBCL) represents approximately 40% of all newly diagnosed non‑Hodgkin …
cell lymphoma (DLBCL) represents approximately 40% of all newly diagnosed non‑Hodgkin …
[PDF][PDF] Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients with
D Lu, T Lu, L Gibiansky, X Li, C Li, P Agarwal… - evolution, 2013 - researchgate.net
A two-analyte integrated population pharmacokinetic (PK) model that simultaneously
describes concentrations of antibody-conjugated monomethyl auristatin E (acMMAE) and …
describes concentrations of antibody-conjugated monomethyl auristatin E (acMMAE) and …